



MAGE-F1 (P-14): sc-103035

BACKGROUND

MAGE-F1 is a 308 amino acid melanoma associated protein. MAGE-F1 contains one MAGE domain and is ubiquitously expressed in adult and fetal tissues. The MAGE family consists of a number of antigens recognized by cytotoxic T lymphocytes. The MAGE genes were initially isolated from different kinds of tumors, and based on their virtually exclusive tumor-specific expression in adult tissues, they have been used as targets for cancer immunotherapy. MAGE genes are believed to encode tumor-rejection antigens and are usually expressed in tumors of different histologic types, but not in normal tissues, with the exception of testis and placenta. MAGE-F1, MAGE-D1, MAGE-D2/JCL-1 and NDN form a group of ubiquitously expressed antigens. This constantly expressed group of proteins suggests some MAGE gene products have a role in normal cell physiology.

REFERENCES

1. Traversari, C., van der Bruggen, P., Luescher, I.F., Lurquin, C., Chomez, P., Van Pel, A., De Plaen, E., Amar-Costesec, A. and Boon, T. 1992. A non-peptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. *J. Exp. Med.* 176: 1453-1457.
2. Zakut, R., Topalian, S.L., Kawakami, Y., Mancini, M., Eliyahu, S. and Rosenberg, S.A. 1993. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. *Cancer Res.* 53: 5-8.
3. Marchand, M., Brasseur, F., van der Bruggen, P., Coulie, P. and Boon, T. 1993. Perspectives for immunization of HLA-A1 patients carrying a malignant melanoma expressing gene MAGE-1. *Dermatol* 186: 278-280.
4. Liu, B.B., Ye, S.L., He, P., Liu, Y.K. and Tang, Z.Y. 1999. MAGE-1 and related MAGE gene expression may be associated with hepatocellular carcinoma. *J. Cancer Res. Clin. Oncol.* 125: 685-689.
5. Ohman Forslund, K. and Nordqvist, K. 2001. The melanoma antigen genes—any clues to their functions in normal tissues? *Exp. Cell Res.* 265: 185-194.
6. Stone, B., Schummer, M., Paley, P.J., Crawford, M., Ford, M., Urban, N. and Nelson, B.H. 2001. MAGE-F1, a novel ubiquitously expressed member of the MAGE superfamily. *Gene* 267: 173-182.

CHROMOSOMAL LOCATION

Genetic locus: MAGEF1 (human) mapping to 3q27.1.

SOURCE

MAGE-F1 (P-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of MAGE-F1 of human origin.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-103035 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

MAGE-F1 (P-14) is recommended for detection of MAGE-F1 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with other MAGE family members.

Suitable for use as control antibody for MAGE-F1 siRNA (h): sc-78398, MAGE-F1 shRNA Plasmid (h): sc-78398-SH and MAGE-F1 shRNA (h) Lentiviral Particles: sc-78398-V.

Molecular Weight of MAGE-F1: 35 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.